Marshall Wace, LLP Stoke Therapeutics, Inc. Transaction History

Marshall Wace, LLP

$74.4 Billion
Q1 2025

A detailed history of Marshall Wace, LLP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 2,131,783 shares of STOK stock, worth $28.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,131,783

Previous 951,432 124.06%

Holding current value

$28.9 Million

Previous $10.5 Million 35.09%

% of portfolio

0.02%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$6.65 - $12.74 $7.85 Million - $15 Million	1,180,351 Added 124.06%	2,131,783 $14.2 Million
Q4 2024 Feb 13, 2025	SELL	$10.8 - $13.92 $7.77 Million - $10 Million	-719,301 Reduced 43.05%	951,432 $10.5 Million
Q3 2024 Nov 14, 2024	BUY	$12.24 - $15.92 $6.24 Million - $8.11 Million	509,696 Added 43.9%	1,670,733 $20.5 Million
Q2 2024 Aug 14, 2024	BUY	$11.03 - $17.52 $10.8 Million - $17.2 Million	982,451 Added 550.13%	1,161,037 $15.7 Million
Q1 2024 May 15, 2024	BUY	$4.12 - $14.17 $735,774 - $2.53 Million	178,586 New	178,586 $2.41 Million
Q3 2023 Nov 14, 2023	BUY	$3.78 - $11.99 $181,443 - $575,531	48,001 New	48,001 $189,000
Q3 2022 Nov 14, 2022	BUY	$12.56 - $22.53 $258,949 - $464,501	20,617 New	20,617 $265,000
Q2 2022 Aug 15, 2022	SELL	$10.36 - $23.93 $178,575 - $412,481	-17,237 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$17.19 - $26.1 $432,569 - $656,780	-25,164 Reduced 59.35%	17,237 $362,000
Q4 2021 Feb 14, 2022	BUY	$18.11 - $30.72 $767,882 - $1.3 Million	42,401 New	42,401 $1.02 Million

Others Institutions Holding STOK

# of Institutions

133

Shares Held

60M

Call Options Held

5.6K

Put Options Held

142K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $535M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Stoke Therapeutics, Inc. Transaction History